🎙️  Our PsO Playbook: Brothers on the Fairway, Biologics Experts in the Clinic ⛳️🧬✨

What happens when two Ontario derms  swap the golf course for the Skin and Joints studio? 

You get a rapid-fire, real-world deep dive into bimekizumab for plaque psoriasis—complete with candid golf confessions, myth-busting on intra-class switching, and a candidiasis reality check you can actually use.

Dr. Ron Vender (80 rounds a season 🙌) and Dr. Jensen Yeung (proud caddy and data devotee) unpack their 16-week, multicentre retrospective review of adults with moderate to severe PsO who’d already tangoed with other IL-17 inhibitors. 

Spoiler: 86 % hit IGA 0/1 and PASI 90, while 63 % nailed PASI 100. Not bad for so-called “tough” patients.

Expect quick-hit pearls on why dual IL-17 A + F blockade matters, how to frame the switch and treatment class conversation in 30 seconds, and why starting with your heaviest hitter first-line might be a good real world strategy️‍♀️💡

• Decode the Data 📊
  Translate 16-week real-world outcomes (IGA 0/1, PASI 90/100) into day-to-day decision-making for IL-17–experienced psoriasis patients.
• Master the Switch 🔄
  Compare primary vs secondary non-responders—and justify when intra-class IL-17 switching still makes clinical (and payer) sense.
• Counsel with Confidence 🗣️
  Craft a 30-60-second convo to prep patients to set realistic skin clearance expectations.
• Rethink the Ladder 🪜
  Debate first-line versus “last-resort” positioning the current IL-17 vs IL-23 landscape.
• Plan for Durability 📅
  Identify unanswered questions—1-year persistence, multi-failure cohorts—and how ongoing real-world follow-up could reshape treatment algorithms.

🔔 Hit play, level up your treatment playbook, and maybe even shave a few strokes off your psoriasis management game. #SkinAndJointsPodcast #PsoriasisPearls 🩺

EXCLUSIVE TO THE SKIN AND JOINTS PODCAST 

Dr. Ron Vender is a Dermatologist who currently practices in Hamilton. He is the founder and director of Dermatrials Research Incorporated and Venderm Innovations in Psoriasis. He has participated as principal investigator in over 100 clinical trials. He is Associate Clinical Professor at McMaster University in the Department of Medicine, Division of Dermatology. Dr. Vender serves on the editorial board of the Journal of Cutaneous Medicine and Surgery reviewer for the JEADV, JAAD, and BJD. He is one of eight Canadians elected to the International Psoriasis Council, a member of the Canadian Professors of Dermatology and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis. He represents Canada on several global educational steering committees as well as international advisory boards. He has published over 100 peer-reviewed manuscripts and has had posters, abstracts and lectures presented internationally.

Dr. Jensen Yeung obtained a B.Sc. (Honours) and MD from McMaster University in 2001. In the same year, he began his dermatology residency training at the University of Toronto. During his residency training, he spent 6 months in Australia, New York, and Boston gaining clinical experience and acquiring the newest knowledge in the field of melanoma and dermoscopy from leading experts. In 2005, he was selected by the residency program as the co-chief resident for the year. Having obtained his board certification from the Royal College of Physicians and Surgeons of Canada in 2006, he joined the Faculty of Dermatology at the University of Toronto, where he ran teaching clinics at both Women’s College Hospital and the Sunnybrook Health Sciences Centre. In 2007, he was promoted to the position of medical director for the RKS Dermatology Program at Women’s College Hospital, where he ran a melanoma, psoriasis, and General Dermatology clinic. In 2013, he switched from RKS to PERC and took on the new role as the medical director of PERC (phototherapy education and research centre) where he runs weekly psoriasis/phototherapy clinic. 

In 2014, he and Dr. Dana Jerome started a monthly combined psoriasis/psoriatic arthritis clinic at PERC. In 2011, he joined Dr. Kim Papp’s research facility in Waterloo and has participated in over 200 phase 1 to 4 clinical trials. He has also supervised and mentored many research students and residents, which has led to around 180 peer-reviewed publications. He is an associate editor at JCMS and Canadian Dermatology Today. He has received a number of teaching awards including the best resident teacher award in 2005, the 2008 Women’s College Hospital Department of Medicine Postgraduate Teaching Award, the 2009 University of Toronto Dermatology Postgraduate Program Staff Teaching Award, and the 2023 University of Toronto Department of Medicine Award for Excellence in Postgraduate Teaching.

📻www.skinandjoints.ca

✉️[email protected]

📻www.skinandjoints.ca

✉️[email protected]

🎙️  Before the Referral to Dr. Abdulla: Filling Your Acne 🛒 ‘Shopping Cart’—Rapid-Fire Ingredients & Real-World Care Considerations (Part 3 of 3)

Episode description

While your patient sits on a six-month wait-list for dermatology, their acne isn’t taking a holiday. 

In the finale of our ingredient deep-dive mini-series, Dr. Sonya Abdulla add to the bulging cart: neo-glucosamine 🧴, glycerin 💧, niacinamide ✨, probiotics 🦠, peptides 🧬, and the aisle heroes—salicylic acid, benzoyl peroxide, and retiinol

Dr. Abdulla also tackles a practice gap too many overlook: the act of referral is not a management plan.

Tune in for bite-sized, practical scripts for product layering ➡️🧖‍♀️➡️🌞 and a myth-busting look at the microbiome 🤯

Powered by a rapid-fire Q&A, and (yes) a self-checkout beep 🔊, this episode hands you an expert toolkit 🧰 to keep acne care moving—because ⏱️ timing is everything.

Learning objectives

⏩ – Identify two evidence-based prescription or OTC therapies to start while patients await referral.

🧪 – Compare how neo-glucosamine, glycerin, niacinamide, salicylic acid, benzoyl peroxide & retinol hit the four pillars of acne pathophysiology.

🔍 – Summarize current evidence (and limits) for probiotics & peptides in acne care, guiding realistic patient expectations.

🤝 – List practical tips and resources that keep pharmacists, GPs & dermatologists co-aligned along the acne journey.

#SkinAndJointsPodcast #AcneCare #DermTips #PrimaryCare #PharmacyPearls #SkinBarrier #IngredientDeepDive #StartLowGoSlow #DermEducation #Neutrogena #AcneAisleMiniSeries #SkinAndJointsPodcast #PharmToDerm 🛍️💡

Made possible with the support of Kenvue Neutrogena

Opinions are for educational purposes only and do not replace individualized medical advice.

ABOUT Dr. Sonya Abdulla

Dermatologist, TORONTO, ON

Dr. Abdulla is a board-certified dermatologist in Canada and the USA and has a blended medical and aesthetic dermatology practice at Dermatology on Bloor in Toronto.  She earned her degree from the University of Ottawa, where she was awarded the Dr. André Peloquin Award for excellence in patient care. She completed additional Fellowship training in Dermatologic Laser Surgery and Aesthetic Medicine at the University of Toronto.

Dr. Abdulla is an active member of the Canadian Dermatology Association, American Academy of Dermatology, American Society of Dermatologic Surgery, European Academy of Dermatology and Venereology, Ontario Medical Association, and Canadian Medical Association. Additionally, she is a published author with numerous articles in peer-reviewed scientific journals.

📻www.skinandjoints.ca

✉️[email protected]

🎙️ Skin & Joints Podcast — Acne Aisle Adventure with Dr. Sonya Abdulla (Part 2 of 3) 🎙️

Dr. Sonya Abdulla is back at the mic, and her shopping cart is starting to look like it needs four-wheel drive. This second instalment rockets from benzoyl-peroxide to sulfur’s glow-up (no more rotten-egg vibes), detours into niacinamide’s barrier-boosting superpowers, and lands on why retinol deserves a nightly standing ovation. 🛒💥🧴

Learning Objectives 📚✨

By the end of Part 2, listeners will be able to:

1. Dose & Dispense Like a Pro 
   •  Choose between OTC benzoyl-peroxide and retinol strengths that maximize efficacy while minimizing irritation. 
2. 🧼 Spot-Treat Smarter 
   • Compare sulfur vs. niacinamide vs. hydrocolloid patches for on-demand blemish triage and know when each option is optimally introduced 
3. 🔍 Master the Mixology
   •  o Sequence AM/PM regimens so retinoids and peroxides play nice, and decode proprietary formulas when % labels ghost you. 
4. 🕵️‍♀️ Escalate with Confidence 
   • Recognize red-flags that warrant prescription-strength upgrades or derm referral. 🚑

🔍 Ingredient Sneak Peek — What’s Rolling onto the Conveyor Belt:

• Benzoyl Peroxide: The OG bacteria-slayer
• Sulfur: Acne care’s retro revival
• Niacinamide: The Swiss-army vitamin
• Retinol / Retinaldehyde: Night-shift gene whisperers that keep new breakouts from ever RSVPing.
• Hydrocolloid Patches: Tiny panic rooms for pimples

Catch the full low-down (percentages, pro hacks, and combo tricks) in the episode—your shopping cart will never be the same. 🎧🛒💥

#AcneAisleMiniSeries #SkinAndJointsPodcast #PharmToDerm 🛍️💡

Made possible with the support of Kenvue Neutrogena

ABOUT Dr. Sonya Abdulla

Dermatologist, TORONTO, ON

Dr. Abdulla is a board-certified dermatologist in Canada and the USA and has a blended medical and aesthetic dermatology practice at Dermatology on Bloor in Toronto.  She earned her degree from the University of Ottawa, where she was awarded the Dr. André Peloquin Award for excellence in patient care. She completed additional Fellowship training in Dermatologic Laser Surgery and Aesthetic Medicine at the University of Toronto.

Dr. Abdulla is an active member of the Canadian Dermatology Association, American Academy of Dermatology, American Society of Dermatologic Surgery, European Academy of Dermatology and Venereology, Ontario Medical Association, and Canadian Medical Association. Additionally, she is a published author with numerous articles in peer-reviewed scientific journals.

Made possible with the support of Kenvue Neutrogena

📻www.skinandjoints.ca

✉️[email protected]

🛒 Skin & Joints Podcast — Acne Aisle Adventure (Part 1 of 3) 🛒
Ready to turn the drug‑store shelf into your acne‑fighting playground? In this episode host‑with‑the‑most Erin Sahota tags in Toronto derm dynamo Dr. Sonia Abdulla for a cart‑cramming romp through OTC land. From prairie roots to downtown Toronto chic, Dr. A spills secrets on why salicylic acid is the Beyoncé of beta‑hydroxy acids, how to stop patients from “more‑is‑more” exfoliation crimes, and where pharmacists now fit in the prescription‑plus‑product relay race. Expect real‑talk on field therapy vs. spot shots, evidence‑based label sleuthing, and the brand‑new “Dr. Abdulla’s Shopping Cart” lightning round—because nothing says skin‑science like a checkout beep. 🎧✨

By the end of Part 1, listeners will be able to:

Decode the Acne Aisle: List the must‑know OTC actives (salicylic acid, benzoyl peroxide, retinoids, azelaic acid) and match them to cleanser, leave‑on, and spot‑treatment roles.

Coach Like a Pro: Craft patient counseling that sets realistic timelines (2–12 weeks), emphasizes whole‑field application, and prevents over‑zealous scrubbing sabotage.

Sync the Derm‑Pharm Duo: Describe how expanded pharmacist prescribing for mild acne can bridge access gaps and how consistent messaging keeps patients on track.

Build a Tiered Toolkit: Assemble product “menus” at multiple price points—because evidence‑based care shouldn’t hinge on a wallet size.

Grab your earbuds, your metaphorical basket, and part‑two‑worthy curiosity—the checkout line is just getting started! #SkinAndJointsPodcast #AcneUnlocked #PharmToDerm 🛒🧴💥

ABOUT Dr. Sonya Abdulla

Dr. Abdulla is a board-certified dermatologist in Canada and the USA and has a blended medical and aesthetic dermatology practice at Dermatology on Bloor in Toronto.  She earned her degree from the University of Ottawa, where she was awarded the Dr. André Peloquin Award for excellence in patient care. She completed additional Fellowship training in Dermatologic Laser Surgery and Aesthetic Medicine at the University of Toronto.

Dr. Abdulla is an active member of the Canadian Dermatology Association, American Academy of Dermatology, American Society of Dermatologic Surgery, European Academy of Dermatology and Venereology, Ontario Medical Association, and Canadian Medical Association. Additionally, she is a published author with numerous articles in peer-reviewed scientific journals.

Made possible with the support of Kenvue Neutrogena

📻www.skinandjoints.ca

✉️[email protected]

🎙️ Part 2 – Safety First 🛡️✨

Still basking in Orlando sun, the crew zooms from efficacy fireworks to the serious stuff: a massive 2,500-patient-year integrated safety update on abrocitinib. Dr. Loo runs the numbers so you don’t have to:

• Four-and-a-half years of data, ~1,600 patients, ages 18–39 📊
• No signal for VTE, MACE, or new malignancies despite the boxed-warning hype 🚫❤️‍🩹
• Main watch-out: shingles (herpes zoster) pops more in adults than teens

Dr. Liu’s playbook:

• Benefit → then risk. The speedy itch-relief first, mention nausea/headache next, finish with Black-Box context (RA ≠ AD, pan vs selective JAK).
• Vaccinate, don’t vacillate. Shingrix before, during, or after start—flexibility wins.
• Lab light-touch. CBC, LFTs, creatinine at baseline & month 1, then q6mo.
• Dose dance. 200 mg for “put-out-the-fire” severe cases; 100 mg for teens, 65+ or comorbidity-heavy adults—with room to escalate.

• Summarize long-term safety signals of abrocitinib in moderate–severe AD and contrast them with boxed-warning concerns.
• Apply age- and risk-stratified dosing in shared decision-making for JAK initiation or escalation.

#SkinAndJointsPodcast #AAD2025 #JAKSafety #Abrocitinib #EczemaCare #DermEd #ItchRelief #MedTwitter 🎧
 

Dermatologist  |  London,  ON

Dr Wei Jing Loo is the owner and Medical Director of DermEffects, a cutting edge dermatology centre located in London, Ontario. Dr Loo completed medical school in 1997 with an honours degree from the University of New South Wales in Sydney, Australia. She trained in Internal Medicine and obtained membership in the Royal College of Physicians in the United Kingdom in 1999. She completed her dermatology residency training in Cambridge, United Kingdom and obtained her Certificate of Specialist Training in Dermatology in 2005. She is board certified in Canada and a fellow of the Royal College of Physicians and Surgeons of Canada. She is a member of the Canadian Dermatology Association and American Academy of Dermatology. 

Dr. Loo is at the forefront of the dynamic field of dermatology, serving as an associate investigator for Probity Medical Research. Dr. Loo is an Adjunct Professor at Western University in Ontario. She enjoys teaching and has published her work in many peer-reviewed journals

📻www.skinandjoints.ca

✉️[email protected]

🎙️PART 1: From Dupilumab to Abrocitinib🩺✨

Sun-kissed Orlando sets the stage as we talk all things eczema from dupilumab to abrocitinib—after squeezing in a little Disney magic, of course. 

Listen to fresh poster data on switching stubborn AD patients from dupilumab to abrocitinib and debate whether to hit hard with 200 mg or start slow at 100 mg. Rapid EASI-90 gains, itch-free nights, and a “flat-line” durability curve you’ll actually love?

Along the way you’ll hear:

• The secret sauce for counseling risk-averse AD patients who’ve already weathered methotrexate and cyclosporine.
• Why comorbid alopecia or vitiligo might tip you toward a JAK-first strategy.

• Identify the clinical profile of AD patients who fail or can’t tolerate dupilumab and may benefit from switching to a JAK inhibitor.
• Compare real-world efficacy & speed of response between abrocitinib 100 mg vs 200 mg, and craft pragmatic dose-titration plans.
• Integrate patient-reported outcomes (itch, DLQI) and comorbidity considerations into shared decision-making for advanced AD therapy.

#SkinAndJointsPodcast #AAD2025 #AtopicDermatitis #EczemaCare #JAKinhibitors #Dupilumab #Abrocitinib #DermTwitter #MedEd #Podcast 🎧
 

SUPPORTED BY AN IME GRANT FROM PFIZER.

Dr Wei Jing Loo is the owner and Medical Director of DermEffects, a cutting edge dermatology centre located in London, Ontario. Dr Loo completed medical school in 1997 with an honours degree from the University of New South Wales in Sydney, Australia. She trained in Internal Medicine and obtained membership in the Royal College of Physicians in the United Kingdom in 1999. She completed her dermatology residency training in Cambridge, United Kingdom and obtained her Certificate of Specialist Training in Dermatology in 2005. She is board certified in Canada and a fellow of the Royal College of Physicians and Surgeons of Canada. She is a member of the Canadian Dermatology Association and American Academy of Dermatology. Dr. Loo is at the forefront of the dynamic field of dermatology, serving as an associate investigator for Probity Medical Research. Dr. Loo is an Adjunct Professor at Western University in Ontario. She enjoys teaching and has published her work in many peer-reviewed journals

📻www.skinandjoints.ca

✉️[email protected]

📻www.skinandjoints.ca

✉️[email protected]

Key Questions Answered: 

• What’s the translational takeaway for dermatologists?🩺
• Do these findings reassure you about dose escalation or reduction?🤔
• 15 mg vs. 30 mg-clinic conundrum solved🏷️

🌴☀️ Sunshine, palm trees, and late-breaking dermatology data!

🎙️💡 In this special live episode of the Skin and Joints Podcast, from the AAD 2025 in sunny Orlando, Florida,  we breakdown the FLEX UP late breaking trial results for upadacitinib for moderate to severe atopic dermatitis with with two leading Canadian dermatologists: Dr. Melinda Gooderham and Dr. Angela Law!

They also share their ultimate “conference flexes” 

We go beyond EASI, spotlighting itch control 🤲, quality of life, and real-world relevance 🏥 for all those asking, “So what does this mean practically?

Together, our experts explore how this flexible dosing study answers a longstanding question:

•  Should you start patients on the 15 mg or 30 mg dose, and can you switch between them for better results?

Hear how this late-breaking data might recalibrate your go-to prescribing assessment and whether it’s time to tweak your approach.

The discussion pokes at the trial’s design, why Week 12 and 24 were selected, the importance of itch reduction, and safety data. 

Dr. Gooderham and Dr. Law also weigh in on how these findings might—or might not—revolutionize current clinical practice.

1. FLEX UP Trial Design & Rationale
   • Grasp how the study was structured to evaluate flexible dosing of upadacitinib at 15 mg and 30 mg.
2. Clinical Efficacy Measures
   • Understand the role of EASI 90, NRS, and quality-of-life metrics in gauging patient outcomes.
3. Real-World Implications
   • Examine how FLEX UP data supports practical dosing choices—starting big or small—and equips you to address patient questions about switching doses.
4. Safety & Tolerability
   • Summarize the key safety findings (including VTE, serious infections, and zoster) and how they align with existing JAK-inhibitor data.
5. Future Directions
   • Recognize the need for longer-term follow-up and additional analyses to further refine flexible dosing strategies and patient selection.

🌞 Grab a comfy pair of sneakers 👟 and a protein bar 🍫 because we’re tackling front-line, day-to-day dilemmas in AD management—once and for all! Expect wit, warmth, and wisdom in this fast-paced chat, complete with palm trees, protein bars, and plenty of pro tips. 

ABOUT DR. MELINDA GOODERHAM

Dermatologist, Peterborough, ON 

Dr. Melinda Gooderham is a well-established dermatologist who serves as medical director at the SKiN Centre for Dermatology and the principal investigator for the SKiN Research Centre. Dr. Gooderham received her MD from the University of Western Ontario in 1999 and then completed her Dermatology residency at the University of Toronto in 2004. Before training in medicine, Dr. Gooderham obtained a Bachelor of Science degree from Queen’s University in Kingston in 1992 and a Master of Science degree from the University of Guelph in 1995. Dr. Gooderham is an Assistant Professor at Queens University and works as a Consultant Physician at the Peterborough Regional Health Centre (PRHC). A fellow of the Royal College of Physicians and Surgeons of Canada, she has investigated over 200 clinical trials focusing on inflammatory skin diseases, including psoriasis and atopic dermatitis. Beyond clinical practice, Dr. Gooderham actively contributes to dermatology publications as an author, reviewer, and associate editor, with authorship of over 200 articles. Her passion for education extends to global audiences through engaging lectures on innovative therapies for skin diseases.

Dr. Angela Law is a board certified Dermatologist in both Canada and the United States. She completed her dermatology residency in a joint program at the University of Saskatchewan and Dalhousie University. She is a Clinical Instructor in the Department of Dermatology and Skin Science at UBC, regularly teaching medical students and residents, and runs the Urgent Dermatology Clinic at Mount Saint Joseph’s Hospital. She also has an active dermatology practice in downtown Vancouver.

Dr. Law also runs the Vulvar Dermatology Clinic at Mount Saint Joseph’s Hospital which is an innovative clinic with a focus on Women’s Health within Providence Health Care.

Episode supported by Abbvie.

📻www.skinandjoints.ca

✉️[email protected]

📻www.skinandjoints.ca

✉️[email protected]

🙌 Hands Down at AAD 2025: Delgocitinib and the “Super-Responder” Story 🌴🎧

🐶✨ Puppies in the hall, Snoop after dark, and a late-breaker that might change how you treat chronic hand eczema on Monday. In this AAD 2025 mini-episode of our “Melinda Knows Best” series, Dr. Melinda Gooderham unpacks a fresh subgroup analysis from the DELTA 1/2/3 program in chronic hand eczema (CHE)—what a “super responder” actually is, how long clearance can last off-therapy, and where a non-steroidal topical like delgocitinib could fit for real patients with real lives (and real world adherence). 🖐️🧴

Why queue this up? 🔥 Because it’s rare to get practice-ready signals for CHE: about half of patients hit at least one deep patient-reported threshold by Week 16, and—here’s the eye-opener—after stopping therapy at Week 16, ~⅓ were still clear/almost clear at 8 weeks and ~15% at 12 weeks. 📊⏱️

🎯 What you’ll learn:

1. 🧭Define “super responder” in CHE via three lenses:
2. 📝Read the right scales fast: quick-hit use of HESD, HECSI, and IGA-CHE—and how to translate them into patient-friendly goals.
3. ⏳Set expectations on durability: what “clear/almost clear” really means (that IGA-CHE bar is high) and how to discuss planned pauses without fueling steroid-withdrawal anxiety.
4. 🧴Position a topical, non-steroidal JAK inhibitor thoughtfully: where a topical, non-steroidal JAK inhibitor can slot alongside—or instead of—steroids/phototherapy in moderate–severe CHE, especially for adherence-sensitive hands.
5. 🔁Bridge trials to the clinic rooms: a simple CHE workflow (start → measure → decide → pause → rescue → re-start) anchored to PROs and signs you can track in under 60 seconds.

🔊 Teaser sound bites

• “Not all ‘super responders’ are the same—PROs, consistency, and maintenance tell different parts of the story.” 🎯
• “Clear/almost clear on IGA-CHE is a stringent bar—set it, explain it, and celebrate it.” ✅

🎙️ Hit play for late-breaker highlights🌴😅

#AAD2025 #Dermatology #ChronicHandEczema #CHE #Delgocitinib #TopicalJAK #JAKInhibitors #EczemaCare #HECSI #HESD #IGACHE #PROs #LateBreaker #EvidenceBased #HCP #Derms #GPs #SkinAndJointsPodcast #MelindaKnowsBest #Orlando

ABOUT Dr.Melinda Gooderham, MD, FRCPC ( Dermatology)

Toronto, ON

Melinda Gooderham MD MSc FRCPC Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queens University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada.

Dr. Gooderham has been the principal investigator for over 200 clinical trials and she practices with a focus on inflammatory diseases of the skin. She also contributes to several peer-reviewed dermatology publications as an associate editor, reviewer, and has been an author of 205 articles. She enjoys lecturing to global audiences on new therapies for skin diseases.

📻www.skinandjoints.ca

✉️[email protected]

📻www.skinandjoints.ca

✉️[email protected]

Lights, laughter, and lasers on sebum?! 🤔 Absolutely!

Join us for our first-ever Skin and Joints Podcast episode live at Fall Clinical 2024 in sunny Las Vegas. 

🎰 We’re unveiling our new segment “Cross-Border Talk,” featuring Dr. Zoe Diana Dreyloos (reformed mechanical engineer ✈️ from North Carolina) and Dr. Andrei Medlitsa US-based dermatologist (hello, North Carolina!) and a Canadian colleague (brrr, Calgary!) trade professional pearls and unique perspectives on acne care.

Expect runway-ready insights on:

• The big reveal of Clascoterone cream’s impact on sebum production (yep, they used a “sebum meter!”)
• Brand-new data showing significant improvements in both inflammatory and non-inflammatory acne lesions
• The “golden ticket” to fine dining in Vegas, plus confessions of flight fantasies (hint: not all high-flying action happens at the blackjack table)

If you’re tired of your patients asking, “Doc, how do I zap this shine?”—this is the episode for you. Because (despite the famous saying) what happens in Vegas definitely won’t stay in Vegas this time. Tune in for the scoop on everything from sebum science to top-secret bunker restaurants. 🍸

Episode Learning Objectives

1. Understand the central role of sebum production in acne pathogenesis and how it shapes therapeutic strategies.
2. Evaluate the newly released 12-week clinical data on Clascoterone cream 1%—with measured impact on both inflammatory and non-inflammatory lesions.
3. Discuss the safety and tolerability profile of Clascoterone, including real-world patient adherence considerations.
4. Translate the study’s findings into everyday practice, identifying which acne patients might benefit most from sebum-targeted therapy.
5. Explore future research directions, including combination approaches, longer-term outcomes, and potential applications in severe acne or pore-size reduction.
6. Understand the pivotal role of sebum production in acne pathogenesis and how it shapes therapeutic decisions.
7. Examine the newest 12-week clinical data on Clascoterone cream 1%—including its documented impact on both inflammatory and non-inflammatory acne lesions.
8. Apply practical tips for integrating Clascoterone into real-world regimens, tackling oily skin head-on with confidence.

Get ready to rethink your acne game plan…

Get ready for an antioxidant masterclass 🤓✨— that’ll have you completely rethinking your recommendations! 

ABOUT Dr. Zoe Diana Draelos, MD, FAAD

DERMATOLOGIST, HIGH POINT, NORTH CAROLINA

Zoe Diana Draelos, MD, is a research and clinical board-certified dermatologist and a Fellow of the American Academy of Dermatology. She is in solo private practice in High Point, North Carolina, and a Consulting Professor of Dermatology at Duke University. In 1988, she founded Dermatology Consulting Services, PLLC, to initiate and perform research in aging skin, acne, rosacea, psoriasis, atopic dermatitis, actinic keratoses, eczema, and aesthetic procedures in the cosmetic, OTC drug, and pharmaceutical arenas. Prior to pursuing a medical career, Dr. Draelos completed an undergraduate degree in Mechanical Engineering and was elected a Rhodes Scholar. A member of Sigma Xi research honorary and Alpha Omega Alpha medical honorary, she is author of 14 books including Cosmetics in Dermatology and Hair Cosmetics. She is the editor of Cosmetic Dermatology: Products and Procedures (third edition) and Cosmeceuticals (fourth edition) with translations into 7 languages. She has contributed chapters to 44 textbooks, written 173 posters, served as the principal investigator on 982 studies, written 650 published papers, served on or contributed to 38 journal editorial boards, functioned as the editor-in-chief of the Journal of Cosmetic Dermatology for 10 years, and was a past member of the Board of Directors of the American Academy of Dermatology and the American Society for Dermatologic Surgery. She was elected Vice-President of the American Academy of Dermatology. She is recognized as a pioneer in cosmetic dermatology and received a lifetime achievement award from Health Beauty America for her research and the 2008 DermArts award for her contributions to dermatology. In 2010, she received the Albert Kligman Innovation Award and in 2016 she was awarded a Presidential Citation from the American Academy of Dermatology for her research contributions to advance the specialty. She received the prestigious Maison deNavarre award from the Society of Cosmetic Chemists for her contributions to the art and science of cosmetics in 2017. In 2019, she was the inaugural recipient of the Florence Wall Award from the Society of Cosmetics Chemists naming her as the most influential women in cosmetic science.

ABOUT Dr. Andrei Metelitsa, MD, FRCPC, FAAD

DERMATOLOGIST, CALGARY, AB

Dr. Metelitsa is a Board-Certified Dermatologist in both Canada and United States and is currently a Clinical Professor at the University of Calgary's Faculty of Medicine. He graduated from medical school at the University of Alberta, Canada at the age of 23. He further received a 5-year dermatology training at the University of Alberta. After completing his residency, Dr. Metelitsa pursued an additional 1-year fellowship training in Lasers and Cosmetic Surgery in Boston, Massachusetts at SkinCare Physicians under the direction of world-renowned faculty from Harvard and Yale. Dr Metelitsa’s Special Interests include: Botox and Dysport injections, Restylane and Juvederm Injections (filler), CO2 Laser Rejuvenation, Excel V Laser, Skin Cancer, Psoriasis. Dr. Metelitsa is also a primary investigator for clinical trial for new and novel dermatology conditions at Beacon Dermatology.

SUPPORTED BY SUN PHARMA

📻www.skinandjoints.ca

✉️[email protected]

Hold onto your antioxidants—this episode of the podcast is a full-court press on free radicals! 

When it comes to the science of antioxidants and topical formulations, we have the right person-dermatologist Dr. Mark Lupin debuts as a faculty expert on the podcast to practically decipher what you NEED to know

Also debuting on the podcast, but as a guest co-host, is dermatologist Dr. Vincent Richer who's ready to fire up the hot seat with pharmacist Aaron Sihota to ask  the tough questions.

Don’t miss our RAPID FIRE round where we break down must-know ingredients faster than you can say ‘free radical!’ 🚀🦸

We dust off your old sunscreen routine and show you why slathering on antioxidants might just be your skin’s new secret weapon. Tune in for a fast-paced conversation that hops effortlessly from clinic chairs to concert halls, apples to ferulic acid, and vitamin C to conjugated retinol. Here, myths get busted, fancy science terms get decoded, and you’ll finally learn the ABCs of a top-tier skincare regimen—no sunscreen-shy patients or lost winter gloves required. ☀️🧴🍏

Trust us, this episode is your on-demand playbook reference for practice! 🎧📖

Learning Objectives:

1. Antioxidant Fundamentals: Understand how environmental aggressors cause oxidative stress on the skin and how antioxidants serve as powerful defenders. The latest science on how these mighty molecules supercharge your broad-spectrum sunscreen and reduce UV-induced damage?🌞🔬  ‍🍃
2. Key Ingredients in formulations: Identify evidence-based antioxidant ingredients, learn why they’re paired together, and explore optimal formulation concentrations and pH levels for maximum skin benefits. 🍏🔬
3. Critical Evaluation of Research: Gain tools and strategies to discern credible studies from marketing fluff, ensuring more informed clinical recommendations. 📚🔎
4. Integration into Practice: Discover practical tips for incorporating antioxidants into morning routines, combining them effectively with sunscreens, and managing patient expectations. ⏰✔️
5. Future Directions in Dermatology: Explore the promising frontier of antioxidant research, including their potential to complement medical interventions and the call for standardized validation measures. 🔭🚀

Get ready for an antioxidant masterclass 🤓✨— that’ll have you completely rethinking your recommendations! 

ABOUT DR.MARK LUPIN  MD FRCPC DABD 

VICTORIA, BC

Dr. Lupin is a Board-certified Dermatologist, Founder in 1998 of Cosmedica Laser Centre in Victoria, British Columbia and Chief Clinical Officer of MedSpa Partners Inc.He has degrees in Mathematics, Music and Medicine having studied at the University of Toronto, University of British Columbia, Dalhousie University, Indiana University and the University of Southern California. He has special interests in photodermatology and laser medicine, having studied under Professor John Hawk at St John’s Institute of Dermatology, London, England. He is active with research and education, has additional subspecialty training in Neurology and is past President of the Canadian Laser Aesthetic Surgery Society.

As a concert violinist, Dr Lupin has performed as soloist at Carnegie Hall, New York and with major orchestras around the world.  He is Concertmaster of the World Doctors Orchestra (WDO), performing most recently in Australia at the Sydney Opera House, with all proceeds donated to charities. His research interests extend to space medicine and fluid dynamics where he has been active with mathematical modeling for space tools and has developed several patent pending energy efficient devices.

ABOUT Dr. Vincent Richer MD FRCPC 

VANCOUVER, BC

Dr Vincent Richer practices cosmetic dermatology at Pacific Derm Atelier in Vancouver and holds a position as Clinical Assistant Professor at the University of British Columbia’s Department of Dermatology and Skin Science. He trained at Université de Montréal in Medicine and Dermatology and completed a fellowship in Photobiology and Cutaneous Laser Surgery at UBC. He is involved as a subinvestigator in cosmetic clinical trials, has published 35+ peer reviewed scientific articles and is active in undergraduate, graduate and continuing medical education.

EPISODE SUPPORTED BY SKINCEUTICALS AND SKINBETTER SCIENCE.

📻www.skinandjoints.ca

✉️[email protected]

📻www.skinandjoints.ca

✉️[email protected]